



JANUARY 2014

Cumberland begins promotion and distribution of Omeclamox®-Pak
Cumberland's field sales force begins promoting Omeclamox-Pak to gastroenterologists across the nation.

MARCH 2014

Cumberland announces acquisition of Vaprisol® from Astellas Pharma
Cumberland acquires all assets and assumes full responsibility to market, distribute and manufacture Vaprisol.

MAY 2014

Cumberland and Gloria Pharmaceuticals announce joint research and development investment
China's Gloria Pharmaceuticals and Cumberland together invest \$2 million in Cumberland Emerging Technologies to accelerate the development of new product candidates from regional research centers. CET is majority owned by Cumberland in partnership with Vanderbilt University, the state of Tennessee and Gloria – our new international partner.

2014 Milestones

MARCH 2014

Caldolor® reduces fever in pediatric patients
Data from a pediatric study demonstrates the safety and efficacy of Caldolor in reducing fever in hospitalized children. Caldolor is associated with statistically significant reduction in temperature within the first two hours of dosing.

MAY 2014

Cumberland reports return to profitability
In its first quarter earnings release, Cumberland reports its return to profitability through growth in sales of established brands and the addition of new product sales.

MAY 2014

Cumberland launches Vaprisol® promotion
Cumberland launches active sales and marketing campaign to support Vaprisol.

OCTOBER 2014

Caldolor® improves recovery in adult surgery patients
Results from an investigator study show preoperative intravenous ibuprofen improved the overall quality of recovery including comfort, emotion and pain in patients undergoing laparoscopic cholecystectomy (gallbladder removal) surgery.